Since late 2024, we have been aligned with ABL, Inc. Together we offer scalable support for specialty advanced therapeutic developers from research to commercialization with United States and European locations.
Ascend can support your journey at any scale for:
Gene therapies
Immunotherapies
Oncolytics
Vaccines
Development Based Expertise
All our work comes from a background of developing therapies. When we struggled to find our own CDMOs, we became one. Discover the difference of working with a team with deep chemistry, manufacturing & controls (CMC).
Decades of Biologics, Innovation & Expertise
60+ years custom biologics & vaccines support with 20+ AAV development expertise
Next gen technologies & analytics complemented by deep regulatory acumen
Onsite fill-finish capabilities in multiple US locations
Latest News & Insights
5 November 2025
Ascend Advanced Therapies Identifies microRNAs That Enhance AAV Vector Production
Screen of more than 2,400 microRNAs identifies multiple candidates that significantly enhance vector productivity without compromising quality attributes. Munich,...
Read More8 October 2025
European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
Rockville, Maryland – 8th October, 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its...
Read More28 July 2025
Performance Evaluation of the ABL p24 ELISA Kit for Accurate Lentiviral Vector Titer Determination in Cell and Gene Therapy Applications
The ABL p24 ELISA kit, originally developed for HIV titer determination, has evolved into a critical tool for the...
Read More2 July 2025
The Final Mile: Why Fill/Finish Operations Make or Break Viral Vector Therapies
After years of groundbreaking research and millions in development costs, the future of a revolutionary gene therapy can come...
Read MoreTake your career to a new level with Ascend
Email us at hello@www.ascend-adv.com to share your enthusiasm and expertise and one of our team will be in touch.